Cytonus Therapeutics的动态

ME Therapeutics is expanding! We're moving into new lab space to support our drug research and development efforts. This move will allow us to explore new drug discovery opportunities and enhance our pipeline. https://lnkd.in/effQ7kG4 #BioTech #HealthcareInnovation #DrugDiscovery #ResearchAndDevelopment #CorporateGrowth #CancerResearch #NewFacilities #Innovation #ScientificResearch

Congratulations to Edinburgh-based #biotech Cytomos who has raised ￡5M to scale up production of its cell analysis technology. The round was led by existing investors Archangel Investors Limited with participation from Old College Capital, Scottish Enterprise and the British Business Bank. The capital will be invested in marketing Cytomos its first commercial product, #Celledonia?, built on its cell-analysis technology platform AuraCyt. Celledonia? is a benchtop cell analyser which aims to significantly enhance single-cell analysis, potentially transforming biological drug discovery, development processes, and biologics manufacturing. The business' sights are now set on establishing a foothold in North America, the company has a pipeline of trials planned with global partners and strong interest in co-development opportunities from technology developers and a #pharma company. Cytomos' technology #AuraCyt is an unbiased, scalable cell analysis platform to provide a scalable alternative to current cell analysis systems. Using this platform, Cytomos enables biopharma to bring novel therapies to market by up to 6 months faster and reduce costs by enabling critical decision making earlier. Its scalable nature makes it unique in measuring cellular physiology based on intrinsic single-cell properties. Find out more via tech.eu https://lnkd.in/ebBfms2c #Biotech #CellAnalysis #Cytomos #Biopharma #EdinburghTech #DrugDiscovery #Biologics #SingleCellAnalysis #HealthTech #Innovation

?? Syngene Announces First Quarter Results for FY 2025! ? Commenting on the first quarter, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, “First quarter performance was broadly flat, in line with our expectations, reflecting the dip in funding for US biotechs that has impacted our sector over the last two years. However, the value of US biotech funding has seen a marked improvement in the first half of 2024. It will take a while for this funding to flow into outsourcing activities and Syngene is in a strong position to capture a significant share of the upturn in biotech spending in the months ahead.”? Read the full press release, link in the comments section ?? #Syngene #SyngeneQ1Results #FY25 #Biotech #Pharma

Forbion portfolio company Orbis Medicines, a leader in oral macrocycle drug discovery, has entered into a research collaboration and option to an exclusive license with Vivtex, a biotech company revolutionizing oral biologic therapies. This partnership will empower Orbis to leverage Vivtex's cutting-edge GI-ORIS? platform for gut permeability screening, helping to assess the oral bioavailability of Orbis’ next-generation macrocycle drugs, also known as ‘nCycles’. This collaboration could open the door to groundbreaking advancements in the development of orally available therapies for major diseases. Stay tuned for more updates as they advance this exciting science! #Forbion #PortfolioCompany #OralMedicines #OrbisMedicines #Biotech #DrugDiscovery #nCycles #Vivtex #GIORIS #InnovationInHealthcare Marco Boorsma Tim Lohoff, Ph.D. Vanessa Carle Click on the following link to read the official release: https://lnkd.in/e3F-D8Zv

HCW Biologics partners with WY Biotech to advance immunotherapies ?? Know complete story - https://lnkd.in/dvkhEcUi #HCWBiologics #Partnership #Immunotherapy Min Park, MBA joins Matica Biotechnology, Inc. as new Chief Commercial Officer ?? Know complete story - https://lnkd.in/dntM8hcQ #MaticaBio #Leadership #CCO IDEAYA Biosciences appoints Stu Dorman as Chief Commercial Officer ??? Know complete story - https://lnkd.in/dWsp9RJK #IDEAYA #CCO #Leadership Sapio Sciences partners with Waters Corporation for innovation ?? Know complete story - https://lnkd.in/dmF-6zAn #SapioSciences #WatersCorp #Collaboration

#BioFunding ?? ?? Struggling to Secure Funding,?Biotech Turns to Rednote This is a Class 1 innovative drug, first-in-class, in the synthetic lethality space. Phase 1 clinical trials have been completed with no safety concerns, and no grade 3 or higher adverse events. Synthetic lethality is one of the hottest areas in oncology right now. Yet, despite being a promising FIC pipeline, this project is now stuck waiting for funding to advance to Phase 1b. ??Unable to secure funding, it's turning to REDnote for a bit of luck. This also highlights the urgent need for market understanding, investor patience, and policy guidance in the still-young field of innovative pharmaceuticals. #Biotech #InnovativeDrugs #SyntheticLethality #FundingChallenges #Pharma #Investment?#REDnote#FIC

I am excited to be speaking at #BIOTECHX on 9/17 and 9/18. I'll be diving into "Demystifying FAIR" and exploring why "Data Governance Isn't One Size Fits All." I look forward to engaging with industry leaders on these topics! #biotechnology #datagovernance #dataanalytics #pharmaceuticals #biopharma #datascience

Good news for Cork as Biomarin announce a €60m investment in a new four-story laboratory facility, enabling the company to increase its production capacity for currently approved medicines while creating new room for future growth. #biopharma #investment https://lnkd.in/e7tPz83g

Halfway through #BIO2024 in San Diego! ??? It’s been fantastic meeting so many of you and discussing how our expertise in quantitative pharmacology and PKPD modelling can benefit your R&D efforts. Let’s continue these great conversations! Contact us via the partnering system or reach out to Hayley Close directly to schedule a meeting. Peter Sargent Biotechnology Innovation Organization #biotech #pharma #drugdevelopment #pkpdmodelling #quantitativepharmacology #mathematicalmodelling

Capping with TriLink BioTechnologies, part of Maravai LifeSciences’ #CleanCap AU analog streamlines the process, circumventing these issues. It produces an optimal cap structure with the desired 5′ AU sequence at high yield and efficiency, translating to a faster, cheaper, and more reliable way to manufacture #saRNA vaccines and therapeutics. Learn more at https://lnkd.in/euQi7Dqq